GET DAILY SIGNALSWhy Is Acadia Healthcare Company (ACHC) Stock Up +1.47% Today?
Key Takeaways
- Acadia Healthcare shares gained 1.47% on Friday, closing at $34.51, up $0.50 from the prior session's close of $34.01, extending a remarkable multi-week rally.
- A wave of analyst price-target increases — including bullish revisions from Guggenheim, KeyBanc, TD Cowen, and UBS — has fueled sustained buying momentum throughout July.
- Anticipation ahead of Q2 2026 earnings, scheduled for release on Tuesday, July 28, has kept the stock in focus as traders position for the company's next results.
- The stock is up approximately 143% year-to-date, reflecting a powerful turnaround narrative under returning leadership and improving operational metrics.
- Elevated short interest — roughly 36.6% of the float — has amplified upward moves as bearish bets face pressure during the rally.
- Investors now turn their attention to Tuesday's earnings release, where revenue, EPS, and forward guidance will determine whether the rally holds or reverses.
Opening Summary
ACHC — Acadia Healthcare Company, Inc., the largest stand-alone behavioral healthcare provider in the United States — saw its stock rise 1.47% in Friday's trading session. Shares closed at $34.51, adding $0.50 from Thursday's closing price of $34.01. The move marked the latest leg in a sustained rally that has propelled the behavioral health operator's market capitalization to roughly $3.17 billion. Headquartered in Franklin, Tennessee, Acadia operates a network of approximately 275 facilities with roughly 12,400 beds across 40 states and Puerto Rico, providing inpatient psychiatric, substance abuse treatment, and outpatient behavioral health services.
Analyst Upgrades and Price-Target Increases Drive Momentum
A cluster of bullish analyst actions in July has been the primary catalyst behind ACHC's extraordinary run. On July 14, KeyBanc raised its price target to $40 from $30, maintaining an Overweight rating, while TD Cowen lifted its target to $36 from $30 with a Buy rating. Earlier in the month, UBS boosted its target to $39 from $31, and Guggenheim raised its target to $38 from $31. These revisions collectively signal Wall Street's growing conviction that Acadia's turnaround — anchored by returning CEO leadership, bed-capacity expansion, and improved earnings visibility — is gaining real traction. The stock has now blown past the average analyst price target of approximately $32, suggesting the market is pricing in further operational improvements ahead of the company's Q2 report.
Earnings Anticipation Adds Fuel
Acadia Healthcare is scheduled to release its second-quarter 2026 results after the market closes on Tuesday, July 28, with a conference call set for Wednesday, July 29. Analysts are looking for earnings of approximately $0.33 per share on revenue near $848 million, while the company's own guidance calls for EPS in the $0.30–$0.40 range. The company beat expectations handily in Q1, delivering $0.37 per share versus the $0.28 consensus on revenue of $828.8 million — a 7.6% year-over-year increase. That beat, combined with raised full-year guidance for adjusted EBITDA and EPS, set the stage for the current rally. With the earnings event now just one trading day away, positioning flows and anticipation of another potential beat have contributed to Friday's gains.
Turnaround Narrative and Institutional Accumulation
Since the start of 2026, ACHC has undergone a dramatic transformation. The stock entered the year at $14.19 and has surged roughly 143% year-to-date, driven by a combination of new management, cost discipline, and improving facility-level performance. The return of former CEO leadership, the appointment of David Duckworth as Interim CFO, and a strategic focus on boosting underperforming assets have restored investor confidence. Institutional investors have taken note: Principal Financial Group increased its stake by 27.4% in the first quarter, while other large holders — including Wellington Management, Goldman Sachs, and Jefferies Financial Group — have materially expanded their positions. The stock's addition to the Russell 2000 Index after being dropped from the Russell 1000 has also broadened its institutional ownership base.
Market Context and Trading Activity
Friday's session saw roughly 2.3 million shares change hands, modestly below the three-month average volume of approximately 3.1 million. The stock traded in a range of $34.30 to $35.29, briefly testing but not surpassing the 52-week high of $35.83 set earlier in the week. The broader healthcare provider sector has been relatively steady, with peers such as THC and HCA posting solid Q2 results that buoyed sentiment across the group. Acadia's rally has far outpaced both the healthcare sector and the broader S&P 500, reflecting company-specific catalysts rather than a simple sector tailwind. Notably, short interest remains exceptionally elevated at roughly 36.6% of the float — approximately 21.8 million shares — which has amplified upside moves as short sellers face mounting pressure during the stock's relentless ascent.
What Comes Next for ACHC
The immediate focus for ACHC is Tuesday's Q2 earnings release. Beyond the headline numbers, investors will scrutinize same-facility volume trends, bed-ramp progress at newer facilities, margin trajectories, and updated full-year guidance. Key risks include the company's elevated debt load of roughly $2.69 billion, lingering legal overhangs including a $105 million jury verdict against a subsidiary, and the possibility that the rapid share-price appreciation has already priced in optimistic assumptions about the turnaround. On the bullish side, sustained demand for behavioral health services, expanding insurance coverage, and operational improvements under new leadership could extend the rally further. With the stock having more than tripled from its January lows, the Q2 report represents a critical test of whether the fundamentals can justify the extraordinary re-rating.
Trending AI Robots
For traders seeking data-driven strategies in volatile markets like the one ACHC is navigating, Tickeron's Trending AI Robots page offers a curated selection of AI-powered trading bots designed to adapt to evolving conditions. Tickeron provides hundreds of AI trading bots covering thousands of tickers, but only those demonstrating the strongest real-time performance under current market dynamics are featured in this actively maintained section. Bots span a range of strategies, timeframes, and traded symbols, allowing users to identify approaches aligned with their own risk tolerance and market outlook. Explore the Trending AI Robots page to discover which automated strategies are currently outperforming.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Disclaimers and LimitationsContributor
Harry Richardson — Algorithmic Trader & Strategy Developer Harry is an algorithmic trader specializing in impulse and breakout trading strategies across cryptocurrency and equity markets. With more than 10 years of experience in developing automated trading systems, he focuses on building structured algorithms designed to capture momentum while maintaining strict risk control. His approach combines quantitative analysis, real-market execution, and continuous performance monitoring. Vitalii prioritizes risk management, drawdown control, and strategy stability over short-term optimization, ensuring algorithms are adaptable to changing market conditions. He has developed and tested hundreds of automated strategies, working extensively with live trading environments, forward testing, and portfolio-level algorithm management. His work centers on transforming trading ideas into fully operational, scalable automated systems.
ACHC in upward trend: price rose above 50-day moving average on October 09, 2026
ACHC moved above its 50-day moving average on October 09, 2026 date and that indicates a change from a downward trend to an upward trend. In 40 of 51 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are 78%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.
The 10-day moving average for ACHC crossed bullishly above the 50-day moving average on October 14, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 10 of 14 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 71%.
Following a +4.84% 3-day Advance, the price is estimated to grow further. Considering data from situations where ACHC advanced for three days, in 192 of 296 cases, the price rose further within the following month. The odds of a continued upward trend are 65%.
The Aroon Indicator entered an Uptrend today. In 120 of 187 cases where ACHC Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 64%.
Bearish Trend Analysis
The 10-day RSI Indicator for ACHC moved out of overbought territory on October 15, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 27 similar instances where the indicator moved out of overbought territory. In 21 of the 27 cases, the stock moved lower in the following days. This puts the odds of a move lower at 78%.
The Momentum Indicator moved below the 0 level on October 27, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ACHC as a result. In 67 of 91 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 74%.
The Moving Average Convergence Divergence Histogram (MACD) for ACHC turned negative on October 28, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 50 similar instances when the indicator turned negative. In 32 of the 50 cases the stock turned lower in the days that followed. This puts the odds of success at 64%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ACHC declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 67%.
ACHC broke above its upper Bollinger Band on October 14, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 43 (best 1 - 100 worst), indicating steady price growth. ACHC’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 48 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.409) is normal, around the industry mean (204.120). P/E Ratio (-2.414) is within average values for comparable stocks, (19.084). Projected Growth (PEG Ratio) (0.380) is also within normal values, averaging (2.498). Dividend Yield (0.000) settles around the average of (0.091) among similar stocks. P/S Ratio (0.758) is also within normal values, averaging (2.688).
The Tickeron PE Growth Rating for this company is 97 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ACHC’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 84, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
an operator of a network of behavioral health centers
Industry HospitalNursingManagement
Advertisement